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Abstract Metastatic bone disease in patients with advanced cancer is frequently associated
with skeletal complications. These can be debilitating, causing pain, impaired functioning
and decreased quality of life, as well as reduced survival. This review considers how the man-
agement of metastatic bone pain might be optimised, to limit the considerable burden it can
impose on affected patients. Cancer-related pain is notoriously under-reported and under-
treated, despite the availability of many therapeutic options. Non-opioid and opioid analgesics
can be used; the latter are typically administered with radiotherapy, which forms the current
standard of care for patients with metastatic bone pain. Surgery is appropriate for certain
complicated cases of metastatic bone disease, and other options such as radiopharmaceuticals
may provide additional relief. Treatments collectively referred to as bone-targeted agents
(BTAs; bisphosphonates and denosumab) can offer further pain reduction. Initiation of ther-
apy with BTAs is recommended for all patients with metastatic bone disease because these
agents delay not only the onset of skeletal-related events but also the onset of bone pain. With
evidence also emerging for pain control properties of new anticancer agents, the potential to
individualise care for these patients is increased further. Optimisation of care depends on phys-
icians’ thorough appreciation of the complementary benefits that might be achieved with the
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various agents, as well as their limitations. Appropriate anti-tumour treatment combined with
early initiation of BTAs and adequate analgesia plays a key role in the holistic approach to
cancer pain management and may minimise the debilitating effects of metastatic bone pain.
ª 2016 Amgen Inc. Published by Elsevier Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Managing patients with cancer requires a multidiscip-
linary approach, especially when the cancer has meta-
stasised to bone. Bone metastases frequently cause
complications known as skeletal-related events (SREs),
which are associated with significant morbidity [1],
impaired mobility and social functioning [2], reduced
quality of life (QoL) [2], increased resource utilisation
[3e7] and reduced survival [1,8]. Bone metastases are
particularly common in advanced breast, prostate or
lung cancer [9]; indeed, metastatic bone disease is
evident post mortem in approximately 40e70% of these
patients [1]. Renal cell carcinoma also metastasises to
bone, and multiple myeloma invariably spreads to
multiple sites within the bone [10,11]. Here, we review
metastatic bone pain, its impact on patients, and how
management can optimise QoL; implications for clinical
practice are summarised in Table 1.
2. Incidence of metastatic bone pain
Approximately two-thirds of individuals with metastatic
cancer experience pain, which is moderate to severe in
almost half of the cases [12,13]. Often, this pain origin-
ates from primary cancers that have metastasised to
bone. For example, 81.4% of patients with metastatic
cancer reported bone pain, compared with only 23.3%,
10.9%, 7.8% and 0.8% of the same patients reporting
pain that was deemed pleuritic, neural, visceral or
attributable to headache, respectively [14]. Indeed, in
bisphosphonate and denosumab studies in patients with
bone metastases, significant pain was reported at study
entry: mean Brief Pain Inventory (BPI) bone pain scores
were 2.0e4.5 [15e18], mean BPI (Short Form; BPI-SF)
worst pain scores were 4.1e6.3 [18e20], 21e24% of
patients reported moderate bone pain (BPI-SF score
5e6) and 23e35% reported severe bone pain (BPI-SF
score 7e10) [19e22].
3. Aetiology of metastatic bone pain
Metastatic bone pain is complex, originating via in-
flammatory and neuropathic pathways. Tumours may
contain numerous inflammatory cells, and both inflam-
matory cells and tumour cells secrete various pain-
mediating chemicals that activate sensory nerve
endings in the bone. Increased osteoclast activity can
destroy these endings and acidify the environment,
causing neuropathic pain and stimulation of pH-
sensitive nerve endings. Furthermore, osteoclastic bone
loss destabilises bone, causing pain via mechanosensitive
receptors. Bone distension or nerve damage caused by
invading tumours may generate constant pain at rest
and elevate sensitivity to pain during movement
[23e28]. Although periosteal infiltration is rare, perios-
teum stretching may also cause bone distension [29].
SREs, including pathologic fracture, radiation or sur-
gery to bone, and spinal cord compression, may also
cause bone pain [30].
4. Impact of bone metastases and SREs on pain and QoL
Patients with metastatic breast cancer experiencing on-
study SREs reported increased pain, and pain interfer-
ence with daily functioning, compared with those with
no on-study SREs [31]. Meta-analyses also show that
SREs in patients with metastatic cancer significantly
increase the risk of pain progression and the need for
strong opioids (Fig. 1) [32]. Furthermore, SRE-
associated pain may persist despite strong opioid use,
such that patients might not recover fully [32]. Cancer-
related pain can markedly reduce QoL [33], negatively
affecting mood, work, relationships, the ability to walk
[34,35] and sleep [34,36]. Sleep disturbance can further
perturb pain tolerance thresholds, potentially leading to
a vicious cycle of pain [37].
4.1. Assessing metastatic bone pain and related impact on
QoL
There are many tools for evaluating metastatic bone
pain and its impact on QoL [38] (Table 2). The value
of routinely assessing patient-reported outcomes was
demonstrated recently in patients with metastatic cancer
[39]. One group reported their symptoms between clinic
visits via a Symptom Tracking and Reporting system,
which alerted nurses to severe or worsening symptoms.
Treating physicians received symptom printouts at
visits. Compared with the routine care group, more
patients using Symptom Tracking and Reporting re-
ported improved QoL and fewer reported worsening
QoL; they were also less likely to visit the emergency
room or to be hospitalised, more likely to survive 1
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year, and had better quality-adjusted survival (all
p < 0.05) [39]. These findings demonstrate the potential
power of patient-reported outcome assessments to
improve the precision and patient-centeredness of can-
cer care [40].
5. Therapeutic goals and treatment approaches to bone
pain management
Appropriate pain management is vital for maintaining
good QoL at any disease stage, and treatment must be
individualised to each patient to be successful. Cancer-
induced bone pain is multifactorial; hence, optimal pain
relief may require different strategies for different dis-
ease stages and pain types. Background pain is a dull,
continuous pain that increases with disease progression
and can usually be managed well with traditional anal-
gesics [23]. By contrast, breakthrough pain is a transient
and severe exacerbation of pain that can be idiopathic or
precipitated following specific actions [41], is intermit-
tent, starts suddenly and lasts only briefly, and can
therefore be very difficult to treat [23].
Therapeutic goals for pain management are distinct
from those for preventing SREs. The immediate aim is
to reduce pain at rest and during movement, whereas
long-term goals focus on preventing pain progression
and SREs. For patients with no bone pain, the goal
should be to delay the onset of pain and SREs [32].
Together, these approaches should help to improve pa-
tients’ QoL, allowing them to maintain normal life as
much as possible.
The World Health Organization (WHO) guidelines
for managing cancer-related pain recommend a three-
step ‘analgesic ladder’ approach. Mild pain is addressed
by the use of non-opioid analgesics. If pain persists or
increases, mild opioids should be used, and if pain per-
sists/increases further, strong opioids are recommended.
All treatments should be given promptly and regularly
[42,43].
In addition to opioids, the European Society for
Medical Oncology (ESMO) recommends radiotherapy,
bone-targeted agents (BTAs) (e.g. bisphosphonates and
the RANK ligand inhibitor denosumab) and radio-
pharmaceuticals [44] to reduce pain associated with
bone metastases [30]. Surgery may be appropriate in
selected cases involving spinal cord compression or
requiring bone stabilisation [44]. When conventional
radiotherapy and chemotherapy prove inadequate (e.g.
for spinal metastases, vertebral fractures and/or spinal
instability [45]), percutaneous vertebroplasty may be an
option. It improves pain and QoL when administered
alone [46e48] or in combination with radiotherapy [49],
transarterial embolisation [50] and 125I-seed implanta-
tion [45,51]. The National Institute for Health and Care
Excellence therefore recommends considering verte-
broplasty to alleviate pain and associated disability in
such cases [52]. Other recent developments include
thermoablation techniques, with microwave ablation
and high-intensity focused ultrasound options for the
palliative treatment of painful bone metastases [53].
Despite the many treatment options for managing
cancer-related pain, under-treatment is common [54],
Table 1
Management of metastatic bone pain; implications for clinical
practice.
Implications
Diagnosis Metastatic bone pain can have a
profoundly negative impact on patients’
lives, yet it remains under-reported and
under-treated despite the availability of
numerous therapeutic agents, treatment
guidelines, and assessment tools and
questionnaires
Treatment with opioids
and radiotherapy
Opioids and radiotherapy form the
current standard of care, but may not be
suitable for all the patients; indeed, some
never achieve effective relief with these
treatment modalities. Historic guidelines
on opioid use may also not reflect current
understanding of pain, and optimal relief
may require different strategies at each
disease stage and for different types of
pain
Effect of BTAs The pain-relieving effects of BTAs are well
established, but a lack of clear guidance
regarding which to use and for how long
they may prevent optimal management in
patients receiving these drugs. Even when
guidance exists, such as to initiate BTAs
as soon as bone metastases are diagnosed,
it is not always followed in daily practice
Potential of new
treatments
New therapies (such as
radiopharmaceuticals, enzalutamide and
abiraterone acetate) and combination
therapies may offer additional rapid and
effective pain relief
Monitoring pain There is a clear need to: assess pain
routinely and monitor for changes; tailor
and select the most appropriate therapy;
and identify and reduce barriers to
initiating prompt treatment. Preliminary
evidence suggests that remote patient
symptom-tracking tools may prove
particularly valuable for improving the
speed, precision and patient-centricity of
cancer care
Multidisciplinary
management
The multidisciplinary team also plays an
important role. For example, by taking
the time to listen to patients’ concerns
about treatment and understanding their
unique needs and goals, physicians will be
able to tailor therapy according to the
benefiterisk profiles of individual
patients.
Holistic approach The subjective and variable nature of
patients’ pain perception is potentially
affected by elements of social, emotional
and spiritual pain; these aspects should be
considered when making assessments in
clinical practice.
Abbreviation: BTA, bone-targeted agent.
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which may be due to patient reluctance to report cancer-
related pain [55]. Also, despite improvements in the
quality of cancer pain management over the last two
decades, approximately one-third of patients still do not
receive appropriate pain medication [56]. The extent to
which metastatic bone pain contributes to the burden of
under-treated cancer pain is well established and un-
derlies efforts to promote standardisation of bone pain
assessment in trial settings [57]. The following sections
summarise the key advantages and disadvantages of the
main treatment options.
5.1. Opioids
Opioids form the cornerstone of cancer-based pain re-
lief, but data are inconclusive regarding whether mod-
erate pain should be treated with weak opioids (WHO
step 2) or low-dose morphine (step 3). However, a recent
study in adults with moderate cancer pain suggested
low-dose morphine was more effective, with more pa-
tients achieving clinically meaningful and highly
Table 2
Assessment measures for evaluating metastatic bone pain and the
associated impact on QoL used frequently in interventional clinical
studies.
Pain-related assessment measures
Analgesic Quantification Algorithm [117]
Brief Pain Inventory [118]
Brief Pain Inventory-Short Form [119]
Numerical rating scales (various) [120]
Present Pain Intensity index from the McGilleMelzack Pain
Questionnaire [121]
Rotterdam Symptom Checklist [122]
Verbal rating scales (various) [120]
Visual analogue scales (various) [120]
QoL-related assessment measures
Eastern Cooperative Oncology Group performance status [123]
European Organisation for Research and Treatment of Cancer Quality
of Life Questionnaire-C30 [124]
5-dimension EuroQol questionnaire [125]
Functional Assessment of Cancer TherapydGeneral [126]
Spitzer QoL Index [127]
Abbreviation: QoL, quality of life.
Fig. 1. Proportion of patients using strong opioids (AQA score  3) before and after SREs. (a) Pathologic fracture, (b) radiation to bone,
(c) spinal cord compression and (d) surgery to bone [32]. Study visit 6 is the visit at 6 months before the occurrence of the first on-study
SRE. The dashed vertical line represents the occurrence of the first SRE. Study visit 1 is the first visit after the SRE. For patients with no
SRE, data were not consistently available for months 6, 5 and 4. AQA, Analgesic Quantification Algorithm; SRE, skeletal-related event.
Reproduced from von Moos R et al. Support Care Cancer, Pain and analgesic use associated with skeletal-related events in patients with
advanced cancer and bone metastases. Vol. 24; p1327e37, Fig. 1 ‘Proportion of patients with moderate/severe pain and strong opioid use’
with permission of Springer.
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meaningful reductions in pain intensity on low-dose
morphine than on weak opioids (p < 0.001); adverse
events (AEs) were similar between groups [58]. This
suggests that the WHO analgesic ladder, first established
in 1986, may need to be adapted.
Common opioid-associated AEs include nausea,
vomiting and constipation, but these can generally be
managed with dose adjustments and/or adjuvant anti-
emetics and laxatives [59]. Some opioids should be used
with caution in patients with renal impairment, owing
to the potential for accumulation of renally excreted
metabolites [60]. Response to opioids for chronic can-
cer pain is variable, with many patients being non-
responders or poor responders [61]. Patients may also
be reluctant to take opioids [62]; thus, it is important
that physicians take time to understand patients’ con-
cerns and provide necessary advice to patients and
carers.
5.2. Radiotherapy
Together with opioids, radiotherapy is the treatment of
choice for localised metastatic bone pain [30] and pro-
vides effective pain relief [63e65]. Evidence suggests
that low-dose, short-course radiotherapy schedules may
be as effective as high-dose, protracted programmes
[63,66]. Other factors (e.g. frequency of hospital visits
and treatment tolerability) must also be taken into ac-
count when considering the overall QoL of a patient
receiving radiotherapy [67,68].
Approximately half of the patients receiving radio-
therapy for pain experience benefits within 1e2
weeks, although a complete response may take several
months, and some patients never obtain effective relief
[30,66]. However, a systematic review of single-fraction
conventional palliative radiotherapy found that higher
doses produced statistically superior pain response rates
[64] to lower doses, suggesting that some patients may
benefit from increased doses. Potential drawbacks of
radiotherapy include reports of ‘pain flare’, a temporary
worsening of pain in the treated site [69], and itmay not be
ideal in patients who have widespread pain that is difficult
to localise [30] (in such cases, systemic agents such as
bisphosphonates can be effective alternatives [70]).
5.3. Radiopharmaceuticals
The b-emitting radiopharmaceuticals strontium-89 and
samarium-153 lexidronam are approved for the treat-
ment of metastatic bone pain and can provide complete
reductions in pain with no increase in analgesic use for
up to 6 months, although AEs are frequent [71]
(including myelosuppression, pain flares, leukocytope-
nia and thrombocytopenia [71e73]). Radioisotopic pain
relief typically starts 1e4 weeks after treatment initia-
tion, and mean overall, complete and partial response
rates with strontium-89 have been reported as 76%, 32%
and 44%, respectively [72]. Compared with placebo,
samarium-153 lexidronam improves pain scores and
reduces analgesic use over 4-week periods [74,75].
In contrast to b-emitters, a-emitting radiopharma-
ceuticals have a short path length, which reduces mye-
losuppression [76]. The analgesic efficacy of radium-223
dichloride is being assessed in several tumour types, and
it was recently approved for men with prostate cancer
and bone metastases, but with no visceral metastases
[77]. In such patients, radium-223 improved survival
significantly compared with placebo (median, 14.9
versus 11.3 months, respectively; hazard ratio [HR],
0.70; p < 0.001), and prolonged time to first symptom-
atic skeletal event (median, 15.6 versus 9.8 months,
respectively; HR, 0.66; p < 0.001) [77]. It also reduced
the need for external beam radiotherapy for bone pain
(HR, 0.67; p Z 0.00117) [78] and more patients experi-
enced clinically meaningful improvements in QoL (25%
versus 16%, respectively; pZ 0.02); there were also fewer
AEs with radium-223 chloride than with placebo [77]. Of
the 109 patients participating in the US expanded access
programme and not receiving opioids at baseline, 42%
achieved meaningful pain relief with radium-223 (28%
had worse pain and 18% experienced no change) [79].
5.4. Bone-targeted agents
In metastatic cancers, the efficacy of bisphosphonates
for reducing BPI scores, pain symptoms, analgesic use
and radiation to bone has been well demonstrated
(Table 3) [15,17,80e93]. Pamidronate may also delay
time to pain progression [83] and clodronate may delay
time to first regular use of analgesics [92]. In a single-
centre study comparing clodronate and zoledronic
acid in patients with metastatic prostate cancer, both
agents provided pain relief, but zoledronic acid was
significantly more effective [93]. There is some incon-
sistency, however, in the findings of various studies of
bisphosphonates in this setting, and results also vary
across cancer types [94,95].
The RANK ligand inhibitor denosumab has also
demonstrated efficacy in relation to pain palliation. An
integrated analysis of data from three phase 3 studies in
patients with bone metastases showed that, compared
with zoledronic acid (widely accepted to be the most
effective bisphosphonate [30]), denosumab delayed the
onset of moderate/severe pain by a median of 1.8
months (95% CI 0.76, 0.92; p < 0.001) and delayed
median time to clinically meaningful increases in pain
interference by 2.6 months (95% CI 0.75, 0.92;
p < 0.001) [20]. Progression to strong opioid use was less
common with denosumab than with zoledronic acid
(p < 0.05), as was worsening of QoL (p Z 0.005) [20].
These studies have typically been conducted against a
background of as-needed opioid use. Thus, BTAs
appear to provide an effective therapeutic option for
reducing opioid-mediated pain relief. Studies of BTAs
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Table 3
Key data from pivotal phase 3 trials of agents used to treat bone metastases, focussing on pain and quality of life outcomes.
Study Treatment
groups
Primary
tumour
Study duration N Efficacy: bone pain outcomes Efficacy: QoL outcomes
Adami 1989
[92]
Clodronate
(300 mg i.v. once
daily) versus
placebo
Prostate 4 weeks 13  Mean pain score was significantly lower in
the clodronate group than in the placebo
group at all time points to week 4 (p < 0.01)
 Mean analgesic consumption was signifi-
cantly lower in the clodronate group than
in the placebo group at all time points to
week 4 (p < 0.01)
Body 2004
[80]
Ibandronate
(50 mg p.o. once
daily) versus
placebo
Breast 96 weeks 564  Sustained reductions were observed in bone
pain score for ibandronate (0.1) versus
placebo (þ0.2); pZ 0.001 versus placebo at
study end)
 Analgesic use increased in both groups, but
the increase was significantly smaller in the
ibandronate group than in the placebo
group (0.60 versus 0.85 points, respectively;
p Z 0.019)
 The mean number of 12-week periods with
events requiring radiotherapy to bone
significantly reduced with ibandronate
versus placebo (0.73 versus 0.98; p < 0.001)
 QoL (EORTC QLQ-C30) deteriorated in
both groups; the decrease in QoL was
significantly lower with ibandronate than
with placebo (8.3 versus 26.8 points,
respectively; p Z 0.032)
 On the individual functioning scales of the
EORTC QLQ-C30, ibandronate
significantly improved physical and role
functioning versus placebo (p  0.05)
Diel 2004 [81] Ibandronate
(2 mg or 6 mg i.v.
every 3 or 4
weeks) versus
placebo
Breast 96 weeks 466  Bone pain scores were increased at study
end in the placebo (þ0.19) and ibandronate
2 mg groups (þ0.21), but were significantly
reduced in the ibandronate 6 mg group
(0.28; p < 0.001 versus placebo)
 Mean absolute change in analgesic
requirement was numerically lower in the
ibandronate 6 mg group (0.51 points) than
in the placebo group (0.90 points; p > 0.05)
 Pain was reduced significantly in the
ibandronate 6 mg group (p < 0.05 versus
placebo)
 Mean overall QoL scores decreased to a
lesser extent over 96 weeks for patients
receiving ibandronate 2 mg (18.1) and
6 mg (10.3) than for those receiving
placebo (45.4)
 Overall difference in functioning between
the placebo and ibandronate treatment
groups was statistically significant
(p Z 0.005)
 At study end, patients in the ibandronate
6 mg group showed significantly better
functioning than those in the placebo
group (p Z 0.004), with significantly bet-
ter scores on the domains of physical,
emotional and social functioning, and in
global health status (p < 0.05)
Hortobagyi
1996 [82]
Pamidronate
(90 mg i.v. every
4 weeks) versus
placebo
Breast 12 cycles 382  Bone pain decreased from baseline in the
pamidronate group after 3, 6 and 9 cycles
of treatment versus progressive worsening
 ECOG performance status scores and
Spitzer QoL Index scores worsened from
baseline to study end, with significantly
greater worsening in ECOG performance
(continued on next page)
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Table 3 (continued )
Study Treatment
groups
Primary
tumour
Study duration N Efficacy: bone pain outcomes Efficacy: QoL outcomes
in the placebo group. A similar pattern was
observed for analgesic drug use
 Among patients with pain at baseline,
significantly more individuals in the
pamidronate group than in the placebo
group had decreased pain scores at the last
measurement (44% versus 32%; p Z 0.03)
status scores in the placebo group than in
the pamidronate group (p Z 0.03)
Hultborn
1999 [83]
Pamidronate
(60 mg i.v. every
4 weeks) versus
placebo
Breast 2 years 404  Time to progression of pain was signifi-
cantly delayed with pamidronate compared
with placebo (p < 0.01)
 Patient self-assessment of pain according to
visual analogue scales favoured
pamidronate (not statistically significant)
 Consumption of opioid analgesics was
numerically lower in the pamidronate
group than in the placebo group (pZ 0.14)
 The proportion of patients with a poor
performance status was significantly lower
in the pamidronate group than in the
placebo group (p Z 0.013)
Kohno 2005
[15]
Zoledronic acid
(4 mg i.v. every 4
weeks) versus
placebo
Breast 1 year 228  BPI score was significantly reduced from
baseline at every time point from 4 to 52
weeks in the zoledronic acid group. Patients
in the placebo group reported no change or
an increase from baseline at each time
point. No between group statistics were
reported
 There were no clinically significant differ-
ences between treatment groups in anal-
gesic scores
Lipton 2000
[84]
Pamidronate
(90 mg i.v. every
3e4 weeks)
versus placebo
Breast 2 years 751  Mean pain scores and analgesic scores at
the last study visit increased in both groups,
but the increase was significantly lower in
the pamidronate group than in the placebo
group (p < 0.001)
 For patients with data at 2 years, those in
the pamidronate group experienced a sig-
nificant decrease in mean pain scores
compared with an increase in the placebo
group (p Z 0.015)
 Of patients with pain at baseline (79% in
each group), 40% in the pamidronate group
and 52% in the placebo group experienced
increased pain during the study (pZ 0.003)
 ECOG performance status and QoL
scores worsened from baseline to the last
visit in both groups, although less so in the
pamidronate group compared with the
placebo group (difference versus baseline
not significant for either)
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Saad 2005
[85]
Zoledronic acid
(4 mg i.v. every 3
weeks) versus
placebo
Prostate 9-month
extension
(following a 15-
month core
phase)
422  BPI composite pain scores increased for
both treatment groups over time, but were
consistently lower in the zoledronic acid
group than in the placebo group
(p < 0.05 at 3, 9, 21 and 24 months)
 There was no statistically significant mean
change from baseline analgesic score be-
tween treatment groups
Saad 2010
[86]
Zoledronic acid
(4 mg i.v. every 3
weeks) versus
placebo
Prostate 2 years 422  Zoledronic acid significantly reduced mean
BPI composite pain scores versus placebo
at 3, 9, 21 and 24 months (p  0.03 for each
time point)
 Zoledronic acid produced significant re-
ductions versus placebo in several compo-
nents of the BPI composite, including
interference with sleep, general activities,
mood, walking and enjoyment of life
(p < 0.05)
 No significant differences in performance
status or QoL scores were observed be-
tween the treatment groups during the 24
months of follow-up
Saad 2002
[17]
Zoledronic acid
(4 mg or 8 mg i.v.
reduced to 4 mg
i.v.; every 3
weeks) versus
placebo
Prostate 15 months 643  The mean increase in pain score from
baseline to 15 months was smaller for
zoledronic acid 4 mg (þ0.58; not signifi-
cant) and 8 mg/4 mg (þ0.43; p Z 0.026)
than for placebo (þ0.88)
 Differences in analgesic scores between
groups were not statistically significant
 There was no statistically significant dif-
ference between the groups in mean
ECOG performance status scores, FACT-
G QoL scores or EQ-5D scores
Saad 2004
[87]
Zoledronic acid
(4 mg or 8 mg i.v.
reduced to 4 mg
i.v.; every 3
weeks) versus
placebo
Prostate 2 years (15-
month core; 9-
month extension)
643 randomised
to initial study,
186 continued
into extension
 Mean increase from baseline in BPI score
was significantly smaller with zoledronic
acid 4 mg (þ0.58; pZ 0.024) or 8 mg/4 mg
(þ0.54; p Z 0.013) than with placebo
(þ1.05) at 2 years
 There was no statistically significant dif-
ference between groups in mean change in
analgesic score from baseline to 2 years
Theriault
1999 [88]
Pamidronate
(90 mg i.v. every
4 weeks) versus
placebo
Breast 24 cycles 372  Skeletal morbidity for any radiation to
bone and for radiation to bone for pain
relief was significantly lower in the
pamidronate group than in the placebo
group at 6, 12, 18 and 24 cycles (pZ 0.012,
p Z 0.006, p Z 0.025 and p Z 0.011,
respectively)
 At the final measurement, bone pain scores
had increased (worsened) significantly more
in the placebo group than in the pamidro-
nate group (p Z 0.007)
 ECOG performance status and Spitzer
QoL Index scores worsened from baseline
in both treatment groups, with no statis-
tically significant difference reported be-
tween the two groups
(continued on next page)
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Table 3 (continued )
Study Treatment
groups
Primary
tumour
Study duration N Efficacy: bone pain outcomes Efficacy: QoL outcomes
 Mean analgesic use at 12 cycles and at the
final measurement increased significantly
more from baseline in the placebo group
than in the pamidronate group (p Z 0.001
and p < 0.001, respectively)
Tripathy 2004
[89]
Ibandronate
(20 mg or 50 mg
p.o. once daily)
versus placebo
Breast 96 weeks 435  Bone pain scores (LOCF) increased from
baseline to study end in the placebo group
(þ0.21), whereas there was a reduction in
the ibandronate 20 mg group (0.06;
p Z 0.071) and a slight increase of in the
ibandronate 50 mg group (þ0.03;
p Z 0.201)
 Changes from baseline in mean analgesic
score were þ0.96 for placebo, þ0.43 for
ibandronate 20 mg (p Z 0.006 versus pla-
cebo) and þ0.73 for ibandronate 50 mg
(p Z 0.074 versus placebo)
Tubiana-
Hulin
2001 [90]
Clodronate
(1600 mg p.o.
once daily) versus
placebo
Breast 1 year 144  Patients treated with clodronate had sig-
nificant reductions in pain intensity versus
the placebo group (p Z 0.01; measured
using a visual analogue scale) and signifi-
cantly fewer patients receiving clodronate
required analgesics (p Z 0.02)
Weinfurt
2006 [91]
Zoledronic acid
(4 mg or 8 mg i.v.
reduced to 4 mg
i.v.; every 3
weeks) versus
placebo
Prostate 60 weeks 422  At all 11 assessment times, patients in the
zoledronic acid group reported more
favourable pain responses than those
receiving placebo
 Over the duration of the trial, a typical
patient receiving zoledronic acid had a 33%
chance of a favourable response; a typical
patient receiving placebo, who had a 25%
chance of a favourable response
(p Z 0.036)
Abbreviations: BPI, Brief Pain Inventory; ECOG, Eastern Cooperative Oncology Group; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life
Questionnaire-C30; EQ-5D, 5-dimension EuroQol questionnaire; FACT-G, Functional Assessment of Cancer TherapydGeneral; i.v., intravenous; LOCF, last observation carried forward; p.o., oral
(per os); QoL, quality of life.
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have not generally been designed to assess the speed of
onset of pain relief, but significant separation in pain
scores has occurred as early as 1 week or 4 weeks after
initial treatment [15,92].
For patients with opioid-resistant bone pain, a
loading-dose approach with ibandronate can provide
rapid analgesic relief. Following early promising data
[96,97], an observational study was conducted in pa-
tients with bone pain from newly diagnosed skeletal
metastases [98]. Ibandronate (6 mg intravenous [i.v.]
infusion on 3 consecutive days) significantly decreased
pain intensity on days 3e5 and 5e7 (both p < 0.01),
compared with day 0 [98]. The loading-dose technique
has not yet been evaluated using zoledronic acid
(restricted by the potential for renal toxicity) or
denosumab.
6. Considerations for use of BTAs: applying guidelines in
clinical practice
Clinical practice guidelines recommend using BTAs as
soon as bone metastases are detected, and continuing
use throughout the disease course [30]. In real-world
settings, however, 19% of the patients with breast can-
cer and bone metastases did not receive a BTA until
more than 3 months after bone metastases were detected
[99], and for prostate cancer this proportion was even
higher (28%) [100]. The main reasons for delaying
treatment were a very recent diagnosis [99] and a
perceived low risk of bone complications [100].
Palliative radiotherapy may suffice in patients with
newly diagnosed bone metastases who have only a small
number of non-lytic lesions in low-risk regions; howev-
er, there is no guidance regarding which patients may be
considered low risk for SREs or bone pain. Moreover,
data show that even patients with mild or no pain at
treatment initiation can benefit from bone-targeted
therapy [20].
ESMO guidelines for the management of metastatic
bone pain are presented in Fig. 2 [44]. Based on their ef-
ficacy in delaying SREs, ESMO recommends BTAs in all
patients with bonemetastases, regardless of whether bone
pain is present [30]. Early use of BTAs in patients with no
pain or only mild pain can delay pain progression and
improve QoL [19,101]. For patients already experiencing
bone pain, BTAs may offer additional pain relief to that
provided by opioids and radiotherapy. BTAs may be
particularly effective for patients with widespread pain.
The ESMO guidelines do not offer clear recommenda-
tions regarding selection of BTAs [30] but acknowledge
the potential implications of the mechanism of action of
denosumab. As a circulating antibody, denosumab may
reachmore sites in the bone than bisphosphonates, which
have a strong affinity for hydroxyapatite and sites of
active bone turnover, potentially reducing their distri-
bution across the whole skeleton [30].
The optimal duration of BTA therapy is not
completely defined by ESMO, but continuous treatment
is recommended in patients with progression of under-
lying bone metastases, a recent SRE and/or elevated
bone resorption markers [30]. In real-world practice,
unplanned discontinuations may occur owing to hypo-
calcaemia, risk and presence of osteonecrosis of the jaw
and primary tumour progression [99,100]. A consider-
able proportion of patients may also stop receiving
BTAs owing to completion of planned treatment
[99,100]; indeed, in a large patient chart survey, the most
common reason for discontinuation was reaching the
Uncomplicated bone metastases
Bone pain?
YES NO
Complicated bone metastases
(spinal cord compression or
impending fracture)
Radiotherapy and/or surgery 
when appropriate
AND
Bone-targeted therapya
AND
Analgesic therapy
Bone-targeted
therapya
Bone-targeted
therapya
AND
Analgetic radiotherapy
AND
Analgesic therapy 
Fig. 2. European Society for Medical Oncology guidelines for the management of metastatic bone pain [44]. aProduct-specific guidance
should be adhered to with regards to calcium and vitamin D supplementation, as well as preventive dental screening.
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end of planned treatment [102]. This implies that,
despite the lack of guidance, physicians tend to deter-
mine treatment course length when prescribing BTAs.
When evaluating the benefiterisk profile of long-term
BTA therapy, the potential for SRE prevention, the
patient’s renal function and risk of osteonecrosis of the
jaw should be taken into account.
To address concerns about prolonged monthly
administration of bisphosphonates, several studies have
examined, or are examining, the impact of reducing the
dosing frequency from every 4 weeks to every 12 weeks
[103e106]. Although the completed studies have
confirmed the feasibility of a lower dosing frequency,
suggesting the 12-week regimen may become a future
standard of care, pain and QoL outcomes were not
assessed in all studies. Thus, further trials are needed to
confirm whether or not a reduced dosing frequency af-
fects bone-pain-related outcomes.
7. Developments in metastatic bone pain therapy
7.1. Enzalutamide
Enzalutamide is an androgen-receptor inhibitor approved
for patients with metastatic prostate cancer. In the large,
phase 3 AFFIRM trial, enzalutamide significantly pro-
longed survival in individuals with metastatic castration-
resistant prostate cancer (mCRPC) who had progressed
following docetaxel treatment [107]. Enzalutamide also
prolonged time to first SRE versus placebo (median, 16.7
versus 13.3 months, respectively; HR, 0.69; p < 0.001).
Furthermore, fewer patients reported pain progression at
week 13 (28% versus 39%, respectively; p Z 0.0018) and
more patients reported an overall improvement in QoL
(42% versus 15%, respectively; p < 0.0001) [108]. How-
ever, no studies have compared the efficacy of enzaluta-
mide against an active comparator.
Enzalutamide significantly improved overall survival
and radiographic progression-free survival in men with
chemotherapy-naive mCRPC in an interim analysis of
the PREVAIL trial [109]. Compared with placebo, me-
dian time to QoL deterioration was significantly longer
with enzalutamide, and significantly more patients re-
ported clinically meaningful improvements in various
measures of QoL (all p < 0.0001) [110]. At data cut-off,
fewer patients receiving enzalutamide had experienced
an SRE compared with those receiving placebo (32%
versus 37%, respectively), and median time to first SRE
was 31.1 and 31.3 months, respectively (HR, 0.72;
p < 0.0001) [110].
7.2. Abiraterone acetate
Abiraterone acetate is an androgen synthesis inhibitor
indicated for use in combination with prednisone in pa-
tients with mCRPC. In the phase 3 COU-AA-301 study
in patients previously treated for mCRPC [111,112],
prednisone plus abiraterone offered significant benefits
over prednisone alone in terms of pain relief and delayed
pain progression (both p < 0.01) [112]. In addition, 48%
of patients reported significant improvements in QoL
with abiraterone, compared with 32% in the predni-
sone arm (p < 0.0001) [111]. Similarly, in COU-AA-302
(treatment-naı¨ve patients), abiraterone plus prednisone
significantly delayed time to opiate use (p < 0.001) and
time to pain progression (p Z 0.05), and increased me-
dian time to functional status deterioration (pZ 0.003),
compared with prednisone alone [113].
7.3. Combination therapies
A post hoc analysis of the abiraterone COU-AA-302
study compared patient outcomes with or without
concomitant BTA therapy [114]. Approximately one-
third of all patients were receiving concomitant BTAs,
with zoledronic acid prescribed the most often (93%),
followed by denosumab (6%), then other BTAs (1%).
BTAs added to abiraterone or prednisone promoted
significant improvements to overall survival (risk
reduction 25%; p Z 0.012) and reduced the time to
performance score deterioration (25%; p < 0.001) and
time to opiate use (20%; p Z 0.036) [114].
A number of analyses have also suggested a positive
interaction between BTAs and radium-223, including
the ALSYMPCA study, in which 41% of patients
with mCRPC were receiving bisphosphonates at study
entry [78]. There was a clear delay in development
of symptomatic skeletal events with radium-223 plus
bisphosphonates, compared with placebo (19.6 versus
10.2 months; HR, 0.49; pZ 0.00048), but no significant
effect in patients receiving radium-223 alone (11.8
versus 8.4 months; HR, 0.77; p Z 0.07) [78]. Post hoc
analyses of a prospective study of radium-223 in pa-
tients with metastatic prostate cancer showed that
concomitant use of novel endocrine agents (abiraterone
or enzalutamide) or denosumab prolonged overall sur-
vival compared with radium-223 alone [115]. These data
have encouraged researchers to initiate investigations
into the use of radium-223 combined with hormone
therapy and denosumab in patients with stage IV meta-
static breast cancer [116].
8. Conclusions
Metastatic bone pain has a marked negative impact on
patients’ QoL, and despite numerous therapeutic op-
tions, remains under-treated. Treatment should combine
anti-tumour therapy with BTAs and analgesia. Owing to
their demonstrated efficacy in improving pain, QoL and
skeletal outcomes, BTAs should be initiated as soon as
bone metastases are diagnosed, and treatment duration
tailored to each patient’s benefiterisk profile. As part of
R. von Moos et al. / European Journal of Cancer 71 (2017) 80e9490
a holistic approach to pain management, the comple-
mentary short- and long-term effects of these agents
should be harnessed to help to optimise the quality of
these patients’ lives.
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